Skip to main
FDMT
FDMT logo

FDMT Stock Forecast & Price Target

FDMT Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 15%
Sell 8%
Strong Sell 0%

Bulls say

4D Molecular Therapeutics Inc. has demonstrated promising clinical efficacy through its gene therapy product candidates, particularly in ophthalmology, evidenced by significant visual acuity gains and a notable reduction in injection burdens for patients. The company possesses a strong financial position with an extended cash runway of $505 million projected to sustain operations into 2028, which is strategically advantageous for advancing pivotal trial readouts. Furthermore, 4D's commitment to targeted therapies and alignment with environmental, social, and governance (ESG) principles enhances its growth trajectory, positioning the company favorably for sustainable success in the gene therapy market.

Bears say

4D Molecular Therapeutics faces significant risks that contribute to a negative outlook on its stock, including the potential failure to replicate positive early-stage data in later trials, which could lead to downward price revisions. The company reported a substantial net loss of $160.9 million for the full year 2024, reflecting its non-revenue generating status and the unpredictability of future earnings, underscoring concerns about its financial viability. Additionally, challenges related to manufacturing capacity and the complexity of producing its gene therapy products could hinder the development and commercialization of its product candidates, further exacerbating its financial risks.

FDMT has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 4D Molecular Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 4D Molecular Therapeutics (FDMT) Forecast

Analysts have given FDMT a Buy based on their latest research and market trends.

According to 13 analysts, FDMT has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

4D Molecular Therapeutics (FDMT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.